Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and keeping the price target at $9.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Justin Walsh has given his Buy rating due to a combination of factors related to the promising developments in Actinium Pharmaceuticals’ ATNM-400. The preclinical data presented at the SNMMI Annual Meeting highlighted ATNM-400’s potential in treating advanced prostate cancer, particularly in models resistant to current treatments. The compound demonstrated significant anti-tumor activity and favorable tumor uptake, surpassing existing therapies like Lu-177-PSMA-617 and Ac-225-PSMA-617 in preclinical models.
Moreover, the rapid clearance of ATNM-400 from healthy tissues suggests a potentially safer profile, which is crucial for patient outcomes. Although further information is needed to fully understand the molecular target and potential market opportunity, the current data supports the potential of ATNM-400 as a promising therapeutic option. These factors collectively underpin Walsh’s Buy rating and the $9 price target for Actinium Pharmaceuticals.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.